ArticleThe Journal of pathology2022
The association between the tumor immune microenvironments and clinical outcome in low-grade, early-stage endometrial cancer patients.
Article in The Journal of pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 29 citations in OpenAlex.
- TNFR1 expression on cancer cells mediates immune escape and an immunosuppressive microenvironment.The Journal of experimental medicine · 2026Article
- CD137 agonists in mice suppress germinal center responses by increasing the immunosuppressive activity of follicular regulatory T-cells.The EMBO journal · 2026Article
- TAMs in the Gynecological Tumor Microenvironment: Insights from Cross-Cancer Studies for Immunotherapy.Cancers · 2026Review
- Establishment of a Model to Predict the Prognosis of Endometrial Carcinoma Using Tumor-Infiltrating Lymphocytes Evaluated With Artificial Intelligence: A Retrospective Analysis.Cancer reports (Hoboken, N.J.) · 2026Article
- Deubiquitinases as prognostic biomarker and potential drug target for gynecological cancers.International journal of clinical oncology · 2026Article
- Loss of Ribosomal Protein L22 (RPL22) Expression Identifies a Transcriptional Subset of MLH1-Deficient Endometrial Cancers With Lower Numbers of Tumor-Associated Lymphocytes.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2026Article
- The Proteomic Landscape ofCells · 2025Article
- Activated immune infiltrates expand opportunities for targeted therapy in p53-abnormal endometrial carcinoma.The Journal of pathology · 2025Article
- 4-1BB agonist targeted to fibroblast activation protein α synergizes with radiotherapy to treat murine breast tumor models.Journal for immunotherapy of cancer · 2025Article
- Predicting recurrence risk in endometrial cancer: a multisequence MRI intratumoral and peritumoral radiomics nomogram approach.Frontiers in oncology · 2025Article
- Impact of Timing the Combination of Radiotherapy and PD-1 Inhibitors on Outcomes in Patients with Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2025Article
- Navigating tumour microenvironment in endometrial carcinoma: a comprehensive review integrating immunohistochemistry, single-cell RNA-sequencing and spatial transcriptomics.Frontiers in oncology · 2025Review
- LIN28B promotes the progression of endometrial cancer through upregulating MYC and correlates with immune microenvironment.Frontiers in oncology · 2025Article
- MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers.Journal for immunotherapy of cancer · 2024Article
- Correlation of BUB1 and BUB1B with the development and prognosis of endometrial cancer.Scientific reports · 2024Article
- Endometrioid Endometrial RNA Index Predicts Recurrence in Stage I Patients.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Review
- Spatially resolved tissue imaging to analyze the tumor immune microenvironment: beyond cell-type densities.Journal for immunotherapy of cancer · 2024Review
- Tumor-infiltrating immune cell score as an independent prognostic predictor for endometrial carcinoma: Insights from a comprehensive analysis of the immune landscape.Cancer reports (Hoboken, N.J.) · 2024Article
- The Clinical and Pathological Characteristics of POLE-Mutated Endometrial Cancer: A Comprehensive Review.Cancer management and research · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial tumors show substantial heterogeneity in their immune microenvironment. This heterogeneity could be used to improve the accuracy of current outcome prediction tools. We assessed the immune microenvironment of 235 patients diagnosed with low-grade, early-stage endometrial cancer. Multiplex quantitative immunofluorescence was carried out to measure CD8, CD68, FOXP3, PD-1, and PD-L1 markers, as well as cytokeratin (CK), on tissue microarrays. Clustering results revealed five robust immune response patterns, each associated with specific immune populations, cell phenotypes, and cell spatial clustering. Most samples (69%) belonged to the immune-desert subtype, characterized by low immune cell densities. Tumor-infiltrating lymphocyte (TIL)-rich samples (4%) displayed high CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.